AERI Profile
Aerie Pharmaceuticals, Inc. (AERI) is a biopharmaceutical company focused on developing treatments for patients with glaucoma and other diseases of the eye. The company's lead product, Rhopressa (netarsudil ophthalmic solution), is a once-daily eye drop medication that was approved by the FDA in 2017 for the treatment of intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Rhopressa works by reducing the production of aqueous humor, which is the fluid that builds up in the eye and causes increased IOP. The medication has been shown to be effective in reducing IOP in patients with glaucoma and ocular hypertension, and it has the potential to be a valuable treatment option for these patients.
In addition to Rhopressa, Aerie Pharmaceuticals is also developing other treatments for glaucoma and other eye diseases. The company's pipeline includes several other drug candidates, including Roclatan, a combination of Rhopressa and latanoprost, another medication used to treat glaucoma. Roclatan has shown promising results in clinical trials, and it has the potential to be an even more effective treatment for patients with glaucoma.
Aerie Pharmaceuticals is committed to improving the lives of patients with glaucoma and other eye diseases, and the company's innovative treatments have the potential to make a significant impact in the field of ophthalmology. With its focus on developing effective and safe treatments for patients with these conditions, Aerie Pharmaceuticals is well-positioned to continue to be a leader in the field of eye care.
|
